A phase I, investigator and subject-blind (sponsor unblinded), placebo-controlled dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-02545920 after multiple oral dose administration in subjects with stable schizophrenia
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2018
At a glance
- Drugs Mardepodect (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 17 Sep 2007 Status changed from recruiting to completed.
- 05 Jul 2007 New trial record.